Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 7:22 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1825–1848 of 4,241 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Study Product Clear all
Completed Phase 2 Interventional Results available

Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia

NCT05802173
View directory record Official record
Conditions
Alopecia, Androgenetic
Interventions
TDM-105795, 0.0025%, TDM-105795, 0.02%, TDM-105795 topical vehicle solution
Drug
Lead sponsor
Technoderma Medicines Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
13
States / cities
North Little Rock, Arkansas • Rolling Meadows, Illinois • Plainfield, Indiana + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Nov 3, 2026, 7:22 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

A 16-week Clinical Study Investigating a Dark Spot Corrector Serum in Women With Moderate Discrete Hyperpigmentation

NCT07468175
View directory record Official record
Conditions
Hyperpigmentation, Dark Spots
Interventions
Cosmetic dark spot corrector serum
Other
Lead sponsor
Revision Skincare
Industry
Eligibility
25 Years to 65 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Nov 3, 2026, 7:22 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Apricitabine and Tipranavir When Dosed Alone or Together

NCT00352066
View directory record Official record
Conditions
HIV Infection
Interventions
apricitabine
Drug
Lead sponsor
Avexa
Industry
Eligibility
18 Years to 40 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 23, 2011 · Synced Nov 3, 2026, 7:22 AM EST
Completed Phase 1 Interventional Results available

Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected Adults

NCT03739866
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Lenacapavir, Placebo, B/F/TAF, TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
12
States / cities
Los Angeles, California • Sacramento, California • Torrance, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2021 · Synced Nov 3, 2026, 7:22 AM EST
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Live Attenuated ETEC Vaccine ACE527 With and Without dmLT Adjuvant in Adults

NCT01739231
View directory record Official record
Conditions
Diarrhea
Interventions
ACE527, dmLT, CeraVacx placebo, H10407 challenge strain
Biological
Lead sponsor
PATH
Other
Eligibility
18 Years to 50 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Nov 3, 2026, 7:22 AM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety of Azilsartan Medoxomil in African American Participants With Essential Hypertension

NCT00591253
View directory record Official record
Conditions
Hypertension
Interventions
Azilsartan medoxomil, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
60
States / cities
Alabaster, Alabama • Huntsville, Alabama • Tempe, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2011 · Synced Nov 3, 2026, 7:22 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005

NCT02271412
View directory record Official record
Conditions
Major Depressive Disorder, Recurrent, Unspecified
Interventions
LY03005, Placebo
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 45 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 21, 2015 · Synced Nov 3, 2026, 7:22 AM EST
Recruiting Phase 3 Interventional

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

NCT06989112
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Trastuzumab deruxtecan, Rilvegostomig, Pembrolizumab, Carboplatin, Paclitaxel, Docetaxel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
62
States / cities
Tucson, Arizona • Little Rock, Arkansas • Duarte, California + 56 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 3, 2026, 7:22 AM EST
Completed Phase 1Phase 2 Interventional Results available

Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)

NCT04345601
View directory record Official record
Conditions
Sars-CoV2, Acute Respiratory Distress Syndrome, COVID-19
Interventions
Mesenchymal Stromal Cells, Supportive Care
Biological · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Nov 3, 2026, 7:22 AM EST
Completed Phase 4 Interventional Results available

The Effect of Vericiguat on Peripheral Vascular Function, Patient Health Status and Inflammation

NCT05420012
View directory record Official record
Conditions
Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF)
Interventions
Vericiguat, Placebo
Drug
Lead sponsor
Josef Stehlik
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Nov 3, 2026, 7:22 AM EST
Completed Phase 2 Interventional

Safety and Efficacy of an Anticholinergic Agent for Treatment of Primary Axillary Hyperhidrosis

NCT02193139
View directory record Official record
Conditions
Hyperhidrosis
Interventions
WL8713, 6 mg, WL8713, 12 mg, WL8713, 18 mg, WL8713, 24 mg, Placebo
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2015 · Synced Nov 3, 2026, 7:22 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study Assessing an Insulin Pump-controlling Algorithm to Minimize Hypo and Hyper in Type 1 During CRC Setting

NCT01638299
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Hypo-Hyper Minimizer (HHM) System
Device
Lead sponsor
Animas Corporation
Industry
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
2
States / cities
Santa Barbara, California • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 21, 2012 · Synced Nov 3, 2026, 7:22 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Preventing HIV/STI in Urban Adolescents Via an mHealth Primary Care Intervention

NCT03368456
View directory record Official record
Conditions
HIV/AIDS and Infections, Drug Abuse, Adolescent Behavior, Drug Usage
Interventions
S4E, Usual Care
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
14 Years to 21 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Ypsilanti, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 31, 2022 · Synced Nov 3, 2026, 7:22 AM EST
Completed Phase 2 Interventional

Phase II Multi-Center Study of T89 to Treat Chronic Stable Angina

NCT00797953
View directory record Official record
Conditions
Angina Pectoris
Interventions
T89
Drug
Lead sponsor
Tasly Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
15
States / cities
Tucson, Arizona • Beverly Hills, California • Corona, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2012 · Synced Nov 3, 2026, 7:22 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

MAD Study of IA-14069

NCT05533372
View directory record Official record
Conditions
Healthy, Rheumatoid Arthritis
Interventions
IA-14069, Placebo, Methotrexate
Drug
Lead sponsor
ILAb Co., Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Nov 3, 2026, 7:22 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers

Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories

NCT00247572
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Amphetamine-Related Disorders, Substance-Related Disorders
Interventions
NRP104
Drug
Lead sponsor
New River Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 5, 2007 · Synced Nov 3, 2026, 7:22 AM EST
Completed Phase 3 Interventional

Study to Evaluate the Safety and Bioequivalence of Estradiol Vaginal Inserts, 10 mcg and Vagifem® 10 mcg and Compare to Placebo

NCT01779947
View directory record Official record
Conditions
Atrophic Vaginitis Due to Menopause
Interventions
Estradiol Vaginal Tablets 10 mcg, placebo
Drug
Lead sponsor
Amneal Pharmaceuticals, LLC
Industry
Eligibility
30 Years to 75 Years · Female only
Enrollment
519 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
25
States / cities
Huntsville, Alabama • Montgomery, Alabama • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Nov 3, 2026, 7:22 AM EST
Completed Phase 2 Interventional Results available

MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)

NCT03217136
View directory record Official record
Conditions
Complicated Intra-Abdominal Infection
Interventions
Ceftolozane/Tazobactam, Metronidazole, Meropenem, Placebo for Metronidazole
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
7 Days to 17 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Los Angeles, California • Orange, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Nov 3, 2026, 7:22 AM EST
Completed Not applicable Interventional Results available

Pre-Shave Gel and Brush in Pseudofolliculitis Barbae

NCT03043534
View directory record Official record
Conditions
Pseudofolliculitis Barbae
Interventions
shave gel, Brush
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
20 Years to 60 Years · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Nov 3, 2026, 7:22 AM EST
Completed Phase 3 Interventional

A Multicenter Study of Pseudoephedrine for the Temporary Relief of Nasal Congestion in Children With the Common Cold

NCT01744106
View directory record Official record
Conditions
Nasal Congestion Associated With the Common Cold
Interventions
pseudoephedrine hydrochloride 30 mg tablets, Placebo tablets
Drug
Lead sponsor
Perrigo Company
Industry
Eligibility
6 Years to 11 Years
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
11
States / cities
Anaheim, California • Costa Mesa, California • Boise, Idaho + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2016 · Synced Nov 3, 2026, 7:22 AM EST
Recruiting Phase 4 Interventional Accepts healthy volunteers

ANCHORS Alcohol & Sexual Health Study: UH3 Project

NCT04331704
View directory record Official record
Conditions
Alcohol Use, Unspecified, Substance Use, Sex Behavior
Interventions
PrEP acronym (pre-exposure prophylaxis), Initial Web Survey, Interactive Voice Response (IVR) monitoring, Educational material on alcohol and sexual health behavior, Interactive Voice Response (IVR) assessment with personalized information, Personalized information based on web-based survey responses & standardized information
Drug · Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 30 Years · Male only
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Nov 3, 2026, 7:22 AM EST
Completed Phase 3 Interventional

Therapeutic Equivalence of Diclofenac Sodium Gel 3% vs Solaraze ® in the Treatment of Actinic Keratosis

NCT03826550
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Diclofenac Sodium Gel, Solaraze 3% Topical Gel, Placebo
Drug · Other
Lead sponsor
Encube Ethicals Pvt. Ltd.
Industry
Eligibility
18 Years and older
Enrollment
655 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
24
States / cities
Bryant, Arkansas • San Ramon, California • Coral Gables, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2019 · Synced Nov 3, 2026, 7:22 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Radicle Calm 2: A Study of Health and Wellness Products on Feelings of Anxiety, Stress, and Health Outcomes

NCT05837910
View directory record Official record
Conditions
Anxiety, Stress
Interventions
Calm Active Study Product 1.1 Usage, Calm Active Study Product 1.2 Usage, Calm Active Study Product 1.3 Usage, Placebo Control Form 1, Placebo Control Form 2, Calm Active Study Product 2.1 Usage, Placebo Control Form 3, Calm Active Study Product 3.1 Usage, Placebo Control Form 4, Calm Active Study Product 4.1 Usage
Dietary Supplement
Lead sponsor
Radicle Science
Industry
Eligibility
21 Years to 105 Years
Enrollment
3,853 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Del Mar, California
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Nov 3, 2026, 7:22 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Comprehensive Multi-omics Characterization and Implications of Non-Pharmaceutical Dental Hygiene Product in a Randomized Controlled Large Population Study.

NCT07451782
View directory record Official record
Conditions
Basic Science, Intervention Studies, Biomarker Discovery
Interventions
Oral Lozenges (Tradename pHossident), Water additive (Tradename Protektin)
Dietary Supplement
Lead sponsor
Delta Dental of Minnesota Foundation
Other
Eligibility
18 Years to 80 Years
Enrollment
595 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Nov 3, 2026, 7:22 AM EST